Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

Dietitians Urge Health Ministers To Adopt A National Framework For Home Enteral Nutrition, Australia
Governments could be saving up to $7.88 million a year if they adopt a national home enteral
generic viagra online
Chinese Government Reports Abortion Statistics
Chinese state media on Thursday reported that women in the country have about 13 million abortions annually, the AP/Houston Chronicle reports. According to the China Daily newspaper, the actual number likely is much higher because the 13 million includes abortions performed in hospitals but not unreported procedures performed in rural clinics. Most of the abortions were among single young women who experts say know little about contraception. The paper also said that about 10 million pills for medical abortion are sold annually in the country. China imposed strict population controls in the 1970s that prohibit most couples from having more than one child. For married women, sterilization and the use of intrauterine devices are widely promoted and subsidized. However, Chinese policies typically do not address the needs of unmarried women, even as national attitudes have become more accepting of sex outside of marriage, the AP/Chronicle reports. According to the newspaper, about 62% of the abortions were among unmarried women ages 20 to 29. The Chinese report called the number of abortions "an unfortunate situation" but did not indicate whether the procedures are increasing or decreasing from year to year. National Population and Family Planning Commission official Wu Shangchun is quoted in the report as saying that almost half of the women seeking abortion had used no form of contraception. Wu also said that reducing abortions is a national challenge that requires significant effort. Peking University professor Li Ying said that sex education in China must be improved at the university level and that Chinese parents must do more to teach children about sex (AP/Houston Chronicle, 7/30).
News of the day
Insurers Offer Reform Concessions, But Balk At Small Business Demands
"Employer-provided medical insurance remains the bedrock of the nation"s health care system. And yet, while most big employers still provide health benefits, soaring premiums have meant many small businesses can no longer afford to cover their workers," the New York Times reports. Some are concerned that many such businesses, those with fewer than 100 workers and which employ 40 percent of the labor force, will be left out of the health reform plan incubating in Congress. While insurers have offered key concessions to make it easier for individuals to buy insurance, saying they"ll "sell policies even to people with pre-existing medical conditions, and to stop basing prices on how healthy or sick someone is," the companies appear unwilling to give small employers the same break.
Diagnostics

Collaborative Drug Discovery Partnership To Advance Cancer Drug Development

SRI International, an independent nonprofit research and development organization, has announced that SRI"s Center for Cancer Research was selected by the National Cancer Institute (NCI) for a leading role in the newly-formed "Chemical Biology Consortium" (CBC), a collaborative drug discovery partnership focused on advancing new cancer therapeutics active against novel molecular and genetic cancer targets. Based on its track record of cancer drug discovery and development, SRI was chosen to lead three of the CBC"s research and development centers: Comprehensive Chemical Biology Screening, Chemical Diversity, and Specialized Applications. SRI has decades of experience in successfully identifying, developing and advancing novel compounds into clinical evaluation. SRI"s Center for Cancer Research, comprised of biologists and medicinal chemists with expertise in fundamental and applied cancer research, focuses on the study of tumor microenvironment, tumor metabolism, and aberrant signaling pathways that cause cancer. Through collaborative partnerships, SRI"s Center for Cancer Research has been successful in generating an extensive drug pipeline translating discoveries into beneficial treatments. SRI"s drug discovery process, guided by a combination of biological screens and computational methods, will be a key component of the NCI Chemical Biology Consortium program. "SRI is proud to be selected to join this innovative NCI program and to continue our long-standing support of NCI"s mission to discover, develop, and bring new drugs to cancer patients," said Lidia Sambucetti, Ph.D., senior director of SRI"s Center for Cancer Research. "Our multidisciplinary research team will bring proven expertise in fundamental and applied cancer research, backed by SRI"s fully-integrated preclinical capabilities." The goal of the Chemical Biology Consortium is to discover and develop new cancer therapeutics, particularly those that are beyond the scope of standard biopharmaceutical practice. The CBC will focus on therapeutic opportunities in high-risk, under-represented areas to advance the discovery of compounds active against novel molecular and genetic cancer targets. Sambucetti will serve as the overall principal investigator of SRI"s CBC program and the Comprehensive Chemical Biology Screening Center. She will collaborate with Mary Tanga, Ph.D., an SRI senior director of medicinal chemistry, who will lead the Chemical Diversity Center, and Keith Laderoute, Ph.D., an SRI distinguished scientist, who will lead the Specialized Applications Center. As the principal investigator of the Comprehensive Chemical Biology Screening Center, Sambucetti was invited to join the CBC Steering Committee, an NCI advisory panel that will work to ensure that CBC Centers are efficiently bridging the gap between basic scientific findings and NCI-supported clinical research. To optimize high-quality leads and accelerate the drug discovery process, SRI will be working with BioComputing Group, Inc., a developer of computational screening, hit-to-lead, and lead optimization tools with particular emphasis on structure-guided drug discovery. These tools employ novel molecular descriptors that are derived from active compounds within the target family and from the structure of the target protein that can be applied to the evaluation of compounds from a library as well as compounds not yet synthesized. BioComputing Group, Inc. (www.BioPredict.com) has a significant track record of success in applying its tools in a hypothesis-driven paradigm to accelerate drug discovery efforts of its collaborators and clients, having placed multiple compounds into clinic with significantly reduced numbers of compounds screened and synthesized and with significantly shortened time frames. This project has been funded in whole or in part with Federal Funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-C0-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products or organizations imply endorsement by the U.S. Government. Dina Basin SRI International


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009